Company Carisma Therapeutics, Inc.

Equities

CARM

US14216R1014

Biotechnology & Medical Research

Market Closed - Nasdaq 04:00:00 2024-05-17 pm EDT 5-day change 1st Jan Change
1.41 USD +2.92% Intraday chart for Carisma Therapeutics, Inc. -4.73% -51.88%

Business Summary

Carisma Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on utilizing its proprietary macrophage and monocyte cell engineering platform to develop transformative immunotherapies to treat cancer and other serious diseases. It is developing a pipeline of product candidates, with an initial focus on advancing multiple ex vivo autologous and in vivo CAR-M therapies for the treatment of solid tumors. Its first product candidate, CT-0508, is an ex vivo gene-modified autologous chimeric antigen receptor-monocyte (CAR-Monocyte) cellular therapy intended to treat solid tumors that overexpress human epidermal growth factor receptor 2 (HER2). Its second product candidate, CT-0525, is an ex vivo gene-modified autologous chimeric antigen receptor-macrophage (CAR-Macrophage) cellular therapy intended to treat solid tumors that overexpress HER2. CT-1119 is a mesothelin-targeted CAR-Monocyte that is designed to treat patients with advanced mesothelin-positive solid tumors.

Number of employees: 107

Managers

Managers TitleAgeSince
Founder 34 15-12-31
Chief Executive Officer 59 18-01-31
Director of Finance/CFO 51 21-05-31
Chief Tech/Sci/R&D Officer - 16-12-31
Corporate Officer/Principal - 19-08-31
Human Resources Officer - 23-06-13
General Counsel 60 23-06-13

Members of the board

Members of the board TitleAgeSince
Chief Executive Officer 59 18-01-31
Chairman 68 21-10-31
Director/Board Member 66 22-01-31
Director/Board Member 53 18-05-31
Director/Board Member 65 20-06-30
Director/Board Member 45 23-03-06
Director/Board Member 64 Mar. 31

Share class

VoteQuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 41,542,744 27,945,297 ( 67.27 %) 0 67.27 %

Shareholders

NameEquities%Valuation
5,059,338 12.18 % 8 M $
HealthCap AB
8.180 %
3,398,248 8.180 % 6 M $
2,749,855 6.619 % 5 M $
IP Group Plc /Venture Capital/
6.531 %
2,713,232 6.531 % 4 M $
2,297,546 5.531 % 4 M $
2,215,877 5.334 % 4 M $
BlackRock Advisors LLC
3.991 %
1,657,976 3.991 % 3 M $
Vanguard Fiduciary Trust Co.
3.803 %
1,579,961 3.803 % 3 M $
TPG Group Holdings (SBS) Advisors, Inc.
3.495 %
1,451,881 3.495 % 2 M $
University of Pennsylvania (Investment)
3.014 %
1,252,107 3.014 % 2 M $

Company contact information

Carisma Therapeutics, Inc.

3675 Market Street Suite 200

19104, Philadelphia

+

http://carismatx.com
address Carisma Therapeutics, Inc.(CARM)
  1. Stock Market
  2. Equities
  3. CARM Stock
  4. Company Carisma Therapeutics, Inc.
-40% Exceptional extension: Our subscriptions help you unlock the best investment opportunities.
BENEFIT NOW